Background: We estimated the multiple sclerosis (MS) incidence in the Netherlands for better active monitoring of potential vaccine safety signals. Methods: A retrospective cohort study (1996–2008) was conducted using a population-based general practice research database containing electronic medical records. Additional information was collected to validate incident probable cases. Results: In the source population (648,656 persons), 146 incident probable MS cases were identified. Overall incidence rate was 6.3/100,000 person years (py; 95% CI, 5.2–7.2). In the subgroup in which MS could be fully validated, the incidence increased from 4/100,000 py (95% CI, 3–5) in 1996–2004 to 9/100,000 py in 2007/8 (95% CI, 6–16). This increase was highest among women, but not statistically significantly different by gender. The median lag time between first recorded symptoms and MS diagnosis decreased from 32 months (<1998) to 2 months (>2005). Conclusions: MS is rare in the Netherlands. In recent years, there was a slight increase in the incidence especially among women during the fertile age. This increase coincided with a decrease in lag time between symptoms and diagnosis, both for men and women. This trend should be taken into account in the interpretation of MS cases occurring in a population where new vaccinations will be introduced shortly.

Keywords:
Autoimmune diseases, Multiple sclerosis, Cohort studies, Incidence studies
1.
Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG: Multiple sclerosis. N Eng J Med 2000;343:938–952.
2.
Ruggieri M, Iannetti P, Polizzi A, Pavone L, Grimaldi LME: Multiple sclerosis in children under 10 years of age. Neurol Sci 2004;25(suppl 4):S326–S335.
3.
Martinelli V, Rodegher M, Moiola L, Comi G: Late onset multiple sclerosis: clinical characteristics, prognostic factors and differential diagnosis. Neurol Sci 2004;25:S350–S355.
4.
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vécsei L, Milanov I: The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700–722.
5.
Minderhoud JM, Zwanniken CF: Increasing prevalence and incidence of multiple sclerosis: an epidemiological study in the province of Groningen, the Netherlands; in Firnhaber W, Lauer K (eds): Multiple Sclerosis in Europe: An Epidemiological Update. Darmstadt, Leuchtturm, 1994.
6.
Wraith DC, Goldman M, Lambert PH: Vaccination and autoimmune disease: what is the evidence? Lancet 2003;362:1659–1666.
7.
Siegrist CA: Mechanisms underlying adverse reactions to vaccines. J Comp Pathol 2007;137:S46–S50.
8.
Regner M, Lambert PH: Autoimmunity through infection or immunization? Nat Immunol 2001;2:185–188.
9.
Shoenfeld Y, Aron-Maor A: Vaccination and autoimmunity – ‘Vaccinosis’: a dangerous liaison? J Autoimmun 2000;14:1–10.
10.
European Medicines Agency: Fifth Pandemic Pharmacovigilance Weekly Update. 6 January 2010. EMA/4476/2010.
11.
Hernán MA, Jick SS, Olek MJ, Jick H: Recombinant hepatitis B vaccine and the risk of multiple sclerosis: a prospective study. Neurology 2004;63:838–842.
12.
Mikaeloff Y, Caridade G, Rossier M, Suissa S, Tardieu M: Hepatitis B vaccination and the risk of childhood-onset multiple sclerosis. Arch Pediatr Adolesc Med 2007;161:1176–1182.
13.
Zipp F, Weil JG, Einhaupl KM: No increase in demyelinating diseases after hepatitis B vaccination. Nat Med 1999;5:964–965.
14.
Ascherio A, Zhang S, Hernán MA, Olek MJ, Coplan PM, Brodovicz K, Walker AM: Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001;344:327–332.
15.
Touzé E, Fourrier A, Rue-Fenouche C, Rondé-Oustau V, Jeantaud I, Bégaud B, Alpérovitch A: Hepatitis B vaccination and first central nervous system demyelinating event: a case-control study. Neuroepidemiology 2002;21:180–186.
16.
DeStefano F, Verstraeten T, Jackson LA, Okoro CA, Benson P, Black SB, Shinefield HR, Mullooly JP, Likosky W, Chen RT, Vaccine Safety Datalink Research Group, National Immunization Program, Centers for Disease Control and Prevention: Vaccinations and risk of central nervous system demyelinating diseases in adults. Arch Neurol 2003;60:504–509.
17.
Sturkenboom MCJM, Wolfson C, Roullet E, Heinzlef O, Abenhaim L: Demyelinisation, multiple sclerosis, and hepatitis B vaccination: a population-based study in the UK. Neurology 2000;54(suppl 3):A166.
18.
Health Council of The Netherlands: General Vaccination against Hepatitis B Revisited. The Hague, Health Council of The Netherlands, 2009, publication No 2009/03.
19.
Health Council of The Netherlands: Vaccination against Cervical Cancer. The Hague, Health Council of The Netherlands, 2008, report No 2008/08.
20.
Lamberts H, Wood M, Hofmans-Okkes IM: International primary care classifications: the effect of fifteen years of evolution. Fam Pract 1992;9:330–339.
21.
Van der Lei J, Duisterhout JS, Westerhof HP, van der Does E, Cromme PV, Boon WM, van Bemmel JH: The introduction of computer-based patient records in The Netherlands. Ann Intern Med 1993;119:1036–1041.
22.
Vlug AE, van der Lei J, Mosseveld BM, van Wijk MA, van der Linden PD, Sturkenboom MC, van Bemmel JH: Postmarketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 1999;38:339–344.
23.
Alonso A, Jick SS, Olek MJ, Hernan MA: Incidence of multiple sclerosis in the United Kingdom: findings from a population-based cohort. J Neurol 2007;254:1736–1741.
24.
Fasbender P, Kölmel HW: Incidence of multiple sclerosis in the urban area of Erfurt, Thuringia, Germany. Neuroepidemiology 2008;30:147–151.
25.
Grytten N, Glad SB, Aarseth JH, Nyland H, Midgard R, Myhr K-M: A 50-year follow-up of the incidence of multiple sclerosis in Horaland County, Norway. Neurology 2006;66:182–186.
26.
Koch-Henriksen N, Bronnum-Hansen H, Hyllested K: Incidence of multiple sclerosis in Denmark 1948–1982: a descriptive nationwide study. Neuroepidemiology 1992;11:1–10.
27.
Sundstrom P, Nuystrom L, Forsgren L: Incidence (1988–97) and prevalence (1997) of multiple sclerosis in Vasterbotten County in northern Sweden. J Neurol Neurosurg Psychiatry 2003;74:29–32.
28.
Marrie RA: Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol 2004;3:709–718.
29.
Ebers GC: Environmental factors and multiple sclerosis. Lancet Neurol 2008;7:268–277.
30.
Debouverie M, Pittion-Vouyovitch S, Louis S, Roederer T, Guillemin F: Increasing incidence of multiple sclerosis among women in Lorraine, Eastern France. Mult Scler 2007;13:962–967.
31.
Hirst C, Ingram G, Pickersgill T, Swingler R, Compston DA, Robertson NP: Increasing prevalence and incidence of multiple sclerosis in South East Wales. J Neurol Neurosurg Psychiatry 2009;80:386–391.
32.
Orton SM, Herrera BM, Yee IM, Valdar W, Ramagopalan SV, Sadovnick AD, Ebers GC, for the Canadian Collaborative Study Group: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006;5:932–936.
33.
Gray OM, McDonnell GV, Hawkins SA: Factors in the rising prevalence of multiple sclerosis in the north-east of Ireland. Mult Scler 2008;14:880–886.
34.
Alonso A, Hernán MA: Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurol 2008;71:129–135.
35.
Hader WJ, Yee IML: Incidence and prevalence of multiple sclerosis in Saskatoon, Saskatchewan. Neurology 2007;69:1224–1229.
36.
Mayr WT, Pittock SJ, McClelland RL, Jorgensen NW, Noseworthy JH, Rodriguez M: Incidence and prevalence of multiple sclerosis in Olmsted County, Minnesota, 1985–2000. Neurology 2003;61:1373–1377.
37.
Waldman A, O’Conner E, Tennekoon G: Childhood multiple sclerosis: a review. Ment Retard Dev Disabil Res Rev 2006;12:147–156.
38.
Black S, Eskola J, Siegrist CA, Halsey N, Macdonald N, Law B, Miller E, Andrews N, Stowe J, Salmon D, Vannice K, Izurieta HS, Akhtar A, Gold M, Oselka G, Zuber P, Pfeifer D, Vellozzi C: Importance of background rates of diseases in assessment of vaccine safety during mass immunization with pandemic H1N1 influenza vaccines. Lancet 2009;374:2115–2122.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.